The research company Cessatech reports increased revenue for full-year 2025 compared with the previous year. The operating loss decreased. The board proposes no dividend. Revenue rose to 5.7 million Danish kroner (2.5).Operating result was -15.0 million Danish kroner (-19.1). Result after tax was -10.9 million Danish kroner (-14.7). Earnings per share amounted to -0.60 Danish kroner (-0.85). No ordinary dividend is proposed (0). Cash and cash equivalents amounted to 8.6 million Danish kroner (12.4)."Going forward, we will continue to focus on developing CT001 and building the capacity required to achieve our regulatory and commercial ambitions. Although challenges remain in drug development, we enter the coming year with momentum, confidence and a clear strategic direction," says CEO Jes Trygved in a comment.Cessatech, MDKK20252024Net revenue5.72.5Operating result-15.0-19.1Net income-10.9-14.7Earnings per share, DKK-0.60-0.85Cash and cash equivalents8.612.4Ordinary annual dividend per share, DKK00